<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198766</url>
  </required_header>
  <id_info>
    <org_study_id>Ph 1 INBRX-106</org_study_id>
    <secondary_id>MK3475 KEYNOTE A99</secondary_id>
    <nct_id>NCT04198766</nct_id>
  </id_info>
  <brief_title>Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)</brief_title>
  <official_title>An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inhibrx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inhibrx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, open-label, non-randomized, 4-part Phase 1 trial to determine the&#xD;
      safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose&#xD;
      (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1&#xD;
      checkpoint inhibitor (CPI) pembrolizumab (Keytruda).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">March 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab</measure>
    <time_frame>2-4 years</time_frame>
    <description>Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab</measure>
    <time_frame>2-4 years</time_frame>
    <description>Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab</measure>
    <time_frame>2-4 years</time_frame>
    <description>Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration time curve (AUC) of INBRX-106</measure>
    <time_frame>2-4 years</time_frame>
    <description>Area under the serum concentration time curve (AUC) of INBRX-106 as a single agent and in combination with pembrolizumab will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of INBRX-106</measure>
    <time_frame>2-4 years</time_frame>
    <description>Maximum observed serum concentration (Cmax) of INBRX-106 as a single agent and in combination with pembrolizumab will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough) of INBRX-106</measure>
    <time_frame>2-4 years</time_frame>
    <description>Trough observed serum concentration (Ctrough) of INBRX-106 as a single agent and in combination with pembrolizumab will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of INBRX-106</measure>
    <time_frame>2-4 years</time_frame>
    <description>Time to Cmax (Tmax) of INBRX-106 as a single agent and in combination with pembrolizumab will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of INBRX-106</measure>
    <time_frame>2-4 years</time_frame>
    <description>Frequency of anti-drug antibodies (ADA) against INBRX-106 as a single agent and in combination with pembrolizumab will be determined.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab</measure>
    <time_frame>2-4 years</time_frame>
    <description>Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1).</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab</measure>
    <time_frame>2-4 years</time_frame>
    <description>Tumor response will be determined by immune Response Evaluation Criteria in Solid Tumors (iRECIST).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Part 1 INBRX-106 Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 INBRX-106 Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-106 at the RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 INBRX-106 Escalation in Combination with Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4 INBRX-106 Expansion in Combination with Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastro-esophageal junction adenocarcinoma, renal cell carcinoma, and urothelial (transitional) cell carcinoma will be treated with INBRX-106 at the RP2D in combination with pembrolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INBRX-106 - Hexavalent OX40 agonist antibody</intervention_name>
    <description>The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4).</description>
    <arm_group_label>Part 1 INBRX-106 Escalation</arm_group_label>
    <arm_group_label>Part 2 INBRX-106 Expansion</arm_group_label>
    <arm_group_label>Part 3 INBRX-106 Escalation in Combination with Pembrolizumab</arm_group_label>
    <arm_group_label>Part 4 INBRX-106 Expansion in Combination with Pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Part 3 INBRX-106 Escalation in Combination with Pembrolizumab</arm_group_label>
    <arm_group_label>Part 4 INBRX-106 Expansion in Combination with Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Select Inclusion Criteria:&#xD;
&#xD;
          -  Males or females aged â‰¥18 years.&#xD;
&#xD;
          -  Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non&#xD;
             resectable solid tumors, whose disease has progressed despite all standard therapies&#xD;
             or for whom no further standard or clinically acceptable therapy exists.&#xD;
&#xD;
          -  Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA,&#xD;
             RCC, or TCC, with locally advanced or metastatic, non-resectable disease, which has&#xD;
             progressed despite all standard therapies or for whom no standard or clinically&#xD;
             acceptable therapy exists.&#xD;
&#xD;
          -  Part 4 (expansion cohorts in combination with pembrolizumab): Subjects with melanoma,&#xD;
             HNSCC, G/GEA, RCC, or TCC, or NSCLC, with locally advanced or metastatic, non&#xD;
             resectable disease, which has progressed despite all standard therapies or for whom no&#xD;
             standard or clinically acceptable therapy exists.&#xD;
&#xD;
          -  All subjects with non-squamous NSCLC must have documentation of absence of tumor&#xD;
             activating EGFR mutations and absence of ALK gene rearrangements.&#xD;
&#xD;
          -  PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any&#xD;
             score allowed. Part 4: Combined Positive Score (CPS) â‰¥ 1% (or Tumor Proportion Score&#xD;
             â‰¥1% for NSCLC).&#xD;
&#xD;
          -  Adequate hematologic, coagulation, hepatic and renal function and ECOG score as&#xD;
             defined per protocol.&#xD;
&#xD;
        Select Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to OX40 agonists.&#xD;
&#xD;
          -  Receipt of any investigational product or any approved anticancer drug(s) or&#xD;
             biological product(s) within 4 weeks prior to the first dose of study drug with&#xD;
             certain exceptions.&#xD;
&#xD;
          -  Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and&#xD;
             multiple myeloma)&#xD;
&#xD;
          -  Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent&#xD;
             malignancy whose natural history or treatment does not have the potential to interfere&#xD;
             with the safety or efficacy assessments of INBRX-106.&#xD;
&#xD;
          -  Known or active primary central nervous system (CNS) tumors, leptomeningeal disease&#xD;
             and CNS metastases. Exception: Subjects with previously treated, asymptomatic, and&#xD;
             clinically stable CNS metastases may be allowed study entry if certain criteria apply.&#xD;
&#xD;
          -  Grade â‰¥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation&#xD;
             of prior immunotherapy. Some exceptions as defined per protocol apply.&#xD;
&#xD;
          -  Active autoimmune disease or documented history of autoimmune disease that required&#xD;
             systemic steroids or other immunosuppressive medications. Certain exceptions as&#xD;
             defined in protocol apply.&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medications within 4 weeks prior to the&#xD;
             first dose of study drug. Certain exceptions as defined in protocol apply.&#xD;
&#xD;
          -  History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection&#xD;
             for Parts 1 and 3. Exceptions as defined in protocol for expansion cohorts will apply.&#xD;
&#xD;
          -  Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or&#xD;
             pneumonitis requiring treatment with steroids or other immunosuppressive medications.&#xD;
&#xD;
          -  Clinically significant cardiac condition, including myocardial infarction,&#xD;
             uncontrolled angina, cerebrovascular accident, or other acute uncontrolled heart&#xD;
             disease &lt; 3 months; left ventricular ejection fraction (LVEF) &lt; 50%; New York Heart&#xD;
             Association (NYHA) Class III or IV congestive heart failure; or uncontrolled&#xD;
             hypertension.&#xD;
&#xD;
          -  Active, hemodynamically significant pulmonary embolism within 3 months prior to&#xD;
             enrollment on this trial.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to enrollment on this trial.&#xD;
&#xD;
          -  Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first&#xD;
             dose of study drug.&#xD;
&#xD;
          -  Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC)&#xD;
             or bone marrow (BM) transplantation.&#xD;
&#xD;
          -  Additional in- and exclusion criteria per protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Wagner, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Inhibrx, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Terri Boyea, Director Clin Ops</last_name>
    <phone>858-500-7833</phone>
    <email>terri@inhibrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>New Patient Services</last_name>
      <phone>800-826-4673</phone>
      <email>sthiagarajan@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute - Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Scott</last_name>
      <phone>404-778-4083</phone>
      <email>suzanne.e.scott@emrory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffery Chin</last_name>
      <phone>773-834-5004</phone>
      <email>jchin18@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Harrelson</last_name>
      <phone>319-467-5831</phone>
      <email>Jordan-harrelson@uiowa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Robinson</last_name>
      <phone>616-389-1739</phone>
      <email>Katie.Robinson@startmidwest.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gladys Pierce</last_name>
      <phone>402-691-6972</phone>
      <email>gpierce@nebraskacancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Foote</last_name>
      <phone>503-215-7192</phone>
      <email>ORCanClinRsrch@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Dotson</last_name>
      <phone>210-595-5670</phone>
      <email>kdotson@nextoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Phase 1 Clinical Trial</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Stomach Cancer</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Kidney Cancer</keyword>
  <keyword>Renal Cell Carcinoma</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Urothelial Carcinoma</keyword>
  <keyword>OX40</keyword>
  <keyword>PD-1</keyword>
  <keyword>Pembrolizumab</keyword>
  <keyword>Keytruda</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

